[Anesthetic implications for patients with the thermolabile variant of the methylenetetrahydrofolate reductase gene].
Martín Rubio
A M
AM
Romero Fernández
A B
AB
Aguilar Franco
C
C
Rabadán Alcázar
L
L
Morón de Miguel
C
C
D019943:Amino Acid Substitution; D000772:Anesthesia, Local; D018685:Anesthetics, Inhalation; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000075202:Contraindications; D005492:Folic Acid / Q000097:blood; D005493:Folic Acid Antagonists; D020022:Genetic Predisposition to Disease; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood; D006358:Hot Temperature; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000235:genetics / Q000517:prevention & control*; D007431:Intraoperative Complications / Q000517:prevention & control*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000737:chemistry / Q000235:genetics*; D020125:Mutation, Missense; D009609:Nitrous Oxide; D017354:Point Mutation; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care; D011489:Protein Denaturation; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000235:genetics
D018685:Anesthetics, Inhalation; D000925:Anticoagulants; D000959:Antihypertensive Agents; D005493:Folic Acid Antagonists; D006495:Heparin, Low-Molecular-Weight; D006710:Homocysteine; D005492:Folic Acid; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D009609:Nitrous Oxide